Edgewise Therapeutics, Inc.
EWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001710072
In the last 90 days, Edgewise Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.82B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $8.67M in total
- 2
- 13F holdersQ2 2026, +15 vs. previous quarter
- 226
- 13F valueReported value at the end of Q2 2026
- $4.82B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding EWTX, Q2 2026
No superinvestor reported holding EWTX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Edgewise Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 (view filing)4:52 PM ET | Aug 12 | 2 days | Koch KevinPresident and CEO | SSale | −18.0K | $43.68 | −$785.0K | −25.5%52.5K after | 3 lots |
| Jul 2, 2026 (view filing)5:21 PM ET | Jul 1 | 1 day | Russell Alan JChief Scientific Officer | SSale | −200.0K | $39.41 | −$7.88M | −89.1%24.6K after | 2 lots10b5-1 |
| May 5, 2026 (view filing) | May 4-5 | 1 day | Donovan Joanne M.CMO | SSale | −55.2K | $37.88 | −$2.09M | −92.7%4.37K after | 2 lots |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Donovan Joanne M.CMO | SSale | −28.7K | $32.31 | −$926.1K | −74.9%9.60K after | 10b5-1 |
| Mar 31, 2026 (view filing) | Mar 31 | Same day | Donovan Joanne M.CMO | SSale | −21.3K | $32.12 | −$685.4K | −69.0%9.60K after | 10b5-1 |
| Mar 30, 2026 (view filing) | Mar 27 | 3 days | Donovan Joanne M.CMO | SSale | −16.4K | $30.98 | −$506.8K | −63.0%9.60K after | 2 lots10b5-1 |
| Jan 23, 2026 (view filing)1:34 PM ET | Jan 21 | 2 days | Edris BadreddinDirector | SSale | −115.5K | $29.44 | −$3.40M | −85.4%19.8K after | 5 lots10b5-1 |
| Nov 13, 2025 (view filing)6:06 PM ET | Nov 12 | 1 day | Russell Alan JChief Scientific Officer | SSale | −100.0K | $21.12 | −$2.11M | −81.0%23.4K after | |
| Nov 13, 2025 (view filing) | Nov 11 | 2 days | Fox Jonathan CDirector | PPurchase | +10.7K | $18.64 | +$199.4K | +82.3%23.7K after | |
| Aug 28, 2025 (view filing)4:55 PM ET | Aug 26 | 2 days | Russell Alan JChief Scientific Officer | SSale | −100.0K | $14.60 | −$1.46M | −81.0%23.4K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Edgewise Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 15,518,492 | $630.5M | 11.94% | 00.0% | Unchanged |
| Paradigm Biocapital Advisors LP | 10,215,455 | $415.1M | 7.77% | +2,850,417+38.7% | Added |
| Ra Capital Management, L.P. | 8,392,730 | $341.0M | 2.96% | −2,035,707−19.5% | Reduced |
| BlackRock, Inc. | 6,606,336 | $268.4M | 0.00% | +133,345+2.1% | Added |
| Jupiter Topco LLC | 6,075,331 | $246.9M | 0.10% | +6,075,331 | New |
| FMR LLC | 5,489,135 | $223.0M | 0.01% | +4,472,083+439.7% | Added |
| Novo Holdings A/S | 5,350,000 | $217.4M | 12.62% | 00.0% | Unchanged |
| Driehaus Capital Management LLC | 4,728,623 | $192.1M | 1.11% | +250,681+5.6% | Added |
| Perceptive Advisors LLC | 4,373,974 | $177.7M | 2.76% | −50,000−1.1% | Reduced |
| Vanguard Capital Management LLC | 3,860,670 | $156.9M | 0.00% | +72,509+1.9% | Added |